{
  "extraction_metadata": {
    "timestamp": "2025-10-02T17:15:08.713313",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 10,
    "total_picos": 34,
    "temperature": 0.1
  },
  "picos_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "PICOs": [
        {
          "Population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy: with Child-Pugh A or no hepatic cirrhosis",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy: with Child-Pugh B",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "BSC",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced (unresectable or metastatic) HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "Child-Pugh A patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 5735
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "hepatocarcinoma patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": ""
        },
        {
          "Population": "hepatocarcinoma patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TAE",
          "Outcomes": ""
        },
        {
          "Population": "Child-Pugh A patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Child-Pugh A patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced (unresectable or metastatic) HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib or sorafenib-based therapy",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced (unresectable or metastatic) HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo or placebo-based (without sorafenib) therapy",
          "Outcomes": ""
        },
        {
          "Population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy:  with Child-Pugh A or no hepatic cirrhosis",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "Adult patients with advanced or inoperable hepatocellular carcinoma (HCC) who have not yet received systemic therapy:  with Child-Pugh B",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "BSC",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 5879
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "Adult patients with advanced HCC and adult patients with inoperable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "400 mg sorafenib twice daily for as long as clinical benefit is observed or until unacceptable adverse reactions occur",
          "Outcomes": ""
        },
        {
          "Population": "Treatment naive adult (aged ≥18 years) patients with advanced, unresectable, or metastatic hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 5474
    },
    "EN": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not had previous systemic treatment, only if: they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not had previous systemic treatment, only if: they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 5187
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "PICOs": [
        {
          "Population": "patients aged 18 years or older and diagnosed with locally advanced or metastatic and/ or unresectable HCC with histological/ cytological confirmation or clinical features consistent with the American Association for the Study of the Liver (AASLD) criteria in cirrhotic patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients aged 18 years or older and diagnosed with locally advanced or metastatic and/ or unresectable HCC with histological/ cytological confirmation or clinical features consistent with the American Association for the Study of the Liver (AASLD) criteria in cirrhotic patients",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 5747
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma (HCC) (stage BCLC B or C) who have not received prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "standard of care therapy",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 5538
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with advanced hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        },
        {
          "Population": "patients with hepatocellular carcinoma for whom intentional curative treatment or (continuation of) locoregional or local palliative treatment is not possible or considered medically unnecessary (advanced hepatocellulose cancer)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best care regimen available",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 4512
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/oxyphilic – Hürthle cell) thyroid cancer, refractory to radioactive iodine (ICD10 C73)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": ""
        },
        {
          "Population": "patients with metastatic and locally advanced differentiated thyroid cancer",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "placebo",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 5244
    },
    "PT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 10,
      "ContextTokens": 3267
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Tecentriq (atezolizumab) plus bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "adult patients with advanced or non-resettable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Lenvima (lenvatinib)",
          "Outcomes": ""
        },
        {
          "Population": "patients with HCC with non-viral etiologies",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Tecentriq plus bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients for whom treatment with atezoumab plus bevacizumab is inappropriate",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 5799
    }
  }
}